Royal London Asset Management Ltd. Acquires 331 Shares of Insulet Co. (NASDAQ:PODD)

Royal London Asset Management Ltd. lifted its holdings in Insulet Co. (NASDAQ:PODD) by 1.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 27,030 shares of the medical instruments supplier’s stock after acquiring an additional 331 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Insulet were worth $5,865,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Parkside Financial Bank & Trust raised its holdings in Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares during the last quarter. Wolff Wiese Magana LLC raised its holdings in Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in Insulet during the 4th quarter valued at $34,000. Jones Financial Companies Lllp bought a new stake in Insulet during the 4th quarter valued at $40,000. Finally, Lindbrook Capital LLC raised its holdings in Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 75 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Mark N. Field sold 2,131 shares of Insulet stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares of the company’s stock, valued at approximately $2,737,431.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Insulet news, SVP Mark N. Field sold 2,131 shares of Insulet stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares of the company’s stock, valued at approximately $2,737,431.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy J. Scannell sold 7,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now directly owns 35,586 shares of the company’s stock, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,431 shares of company stock valued at $2,336,346. Company insiders own 0.47% of the company’s stock.

Insulet Stock Down 0.7 %

NASDAQ PODD traded down $1.39 during mid-day trading on Friday, reaching $200.45. The stock had a trading volume of 483,060 shares, compared to its average volume of 716,596. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $298.95. The stock has a market cap of $14.04 billion, a PE ratio of 60.74, a price-to-earnings-growth ratio of 3.63 and a beta of 1.14. The company has a fifty day moving average price of $177.68 and a 200 day moving average price of $185.82. The company has a debt-to-equity ratio of 1.72, a current ratio of 3.74 and a quick ratio of 2.75.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company had revenue of $441.70 million during the quarter, compared to analyst estimates of $424.05 million. During the same period in the previous year, the business earned $0.23 EPS. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. On average, research analysts expect that Insulet Co. will post 3.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PODD. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Redburn Atlantic started coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective on the stock. Barclays decreased their price target on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. OTR Global reissued a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $226.00 to $234.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $239.18.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.